You will be shown a question, followed by excerpts from biomedical research papers. Please answer the question based on the provided context. Do not include any text in your response other than the answer.

Question: What is herceptin?

Context: Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer.
Breast cancer (BCa) is the most common cancer affecting women worldwide. Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in ~20-25% of invasive ductal breast carcinomas and is associated with the more aggressive phenotype. Herceptin, a humanized antibody against HER2, is a standard therapy in HER2-overexpressing cases.
Trastuzumab (Herceptin®), a monoclonal antibody against the ErbB2 (HER2) receptor, has significantly improved clinical outcomes for HER2+ breast cancer patients.
HER2-positive breast cancer correlates with more aggressive tumor growth, a poorer prognosis and reduced overall survival. Currently, trastuzumab (Herceptin), which is an anti-HER2 antibody, is one of the key drugs.
Trastuzumab (Herceptin), a monoclonal antibody against a membrane-proximal epitope in the extracellular region of erbB2, shows a therapeutic effect against a fraction of erbB2-amplified breast tumors.
BACKGROUND & OBJECTIVE  Herceptin is a humanized monoclonal antibody for treating the patients with metastatic breast cancers overexpressing human epidermal growth factor receptor (HER-2).
Clinical use of Herceptin (trastuzumab), which is a humanized monoclonal antibody against HER2, started for patients with HER2-overexpressing breast cancer.
Herceptin (trastuzumab), an anti-HER2 monoclonal antibody, is the first oncogene-targeted therapy to be developed for the treatment of metastatic breast cancer.
Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2 __sup__ + __end_sup__  breast cancer.
Herceptin is a humanised mouse antibody that targets and inactivates HER-2.
BACKGROUND  Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu).
Herceptin is a well-received antibody drug for HER2 positive gastric cancer .
Herceptin is a recombinant humanized Her2 antibody used to treat breast cancer patients with Her2 overexpression .
Herceptin is a monoclonal antibody against HER2 , which is a member of the epidermal growth factor receptor ( ErbB ) family and is overexpressed in many cancers .
Herceptin is a humanized monoclonal antibody for treating the patients with metastatic breast cancers overexpressing human epidermal growth factor receptor ( HER-2) .
Herceptin is a major drug used to treat HER2 positive breast cancer .
Herceptin is a humanized antibody that binds to the product of the HER-2 oncogene.
BACKGROUND Trastuzumab (Herceptin(®)) is a humanized monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2) and is used in the treatment of HER2-overexpressing breast and gastric cancer.
Herceptin is a HER-2 targeted antibody that being widely used for the management of HER-2 positive breast cancer, which demonstrate significant benefits in both the metastatic and adjuvant settings.
Herceptin is a humanised mouse antibody that targets and inactivates HER-2.
Herceptin is a recombinant humanized Her2 antibody used to treat breast cancer patients with Her2 overexpression.
Herceptin is a monoclonal antibody against HER2, which is a member of the epidermal growth factor receptor (ErbB) family and is overexpressed in many cancers.
Herceptin is a humanized monoclonal antibody for treating the patients with metastatic breast cancers overexpressing human epidermal growth factor receptor (HER-2).
Herceptin/Trastuzumab is a humanized IgG1κ light chain antibody used to treat some forms of breast cancer.
Herceptin, an antihuman epidermal growth factor receptor-2 (anti-HER2) monoclonal antibody, is used to treat HER2+ breast cancer.
Herceptin (trastuzumab) is an adjuvant chemotherapy agent used in treatment of certain breast cancers.
Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu).
Herceptin is a second generation tyrosine kinase inhibitor, that serves as an effective and approved oral therapy for patients with HER2-positive breast cancer. Herceptin is an oral, small molecule, poly (ADP-ribose) polymerase inhibitor that binds to HER2 and inhibits HER2 activation. It is approved for the treatment of breast cancer. Trastuzumab (Herceptin(r) [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer. trastuzumab is the standard of care for her2-positive breast cancer Trastuzumab (Herceptin(r) [H]) is the standard of care for HER2-positive locally advanced/metastatic breast cancer and gastric/gastroesophageal junction (GEJ) cancer.  Herceptin is a tyrosine-kinase inhibitor that targets the HER2 receptor oncogene with high affinity and activity. It is approved for treatment of breast cancer.